IRIS UniCatt

Colafigli, Manuela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.654
NA - Nord America 2.295
AS - Asia 857
SA - Sud America 160
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 3
Totale 5.991
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.258
DE - Germania 851
FR - Francia 367
SE - Svezia 364
CN - Cina 330
PL - Polonia 320
SG - Singapore 295
UA - Ucraina 232
IT - Italia 183
BR - Brasile 144
IE - Irlanda 99
GB - Regno Unito 94
ID - Indonesia 59
IN - India 58
FI - Finlandia 53
TR - Turchia 46
RU - Federazione Russa 32
CA - Canada 31
HK - Hong Kong 16
BE - Belgio 14
VN - Vietnam 11
IR - Iran 8
AT - Austria 7
NL - Olanda 7
CZ - Repubblica Ceca 5
EU - Europa 5
JP - Giappone 5
LT - Lituania 5
MA - Marocco 5
AR - Argentina 4
EC - Ecuador 4
PH - Filippine 4
CH - Svizzera 3
KR - Corea 3
MX - Messico 3
TN - Tunisia 3
AU - Australia 2
AZ - Azerbaigian 2
BD - Bangladesh 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
CL - Cile 2
DK - Danimarca 2
DZ - Algeria 2
ES - Italia 2
ET - Etiopia 2
GE - Georgia 2
GR - Grecia 2
IL - Israele 2
KG - Kirghizistan 2
KZ - Kazakistan 2
NO - Norvegia 2
PE - Perù 2
PY - Paraguay 2
ZA - Sudafrica 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CO - Colombia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
HN - Honduras 1
IM - Isola di Man 1
IQ - Iraq 1
IS - Islanda 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MM - Myanmar 1
MY - Malesia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
TW - Taiwan 1
VE - Venezuela 1
Totale 5.991
Salva come PNG Salva come JPEG
Città #
Chandler 469
Kraków 317
Ashburn 172
Singapore 170
Jacksonville 163
New York 127
San Mateo 120
Dublin 97
Nanjing 90
Dearborn 73
Wilmington 62
Jakarta 59
Houston 58
Ann Arbor 54
Nürnberg 47
Milan 46
Lawrence 45
Cattolica 43
Boston 42
Izmir 41
Redmond 41
Nanchang 37
Woodbridge 32
Redwood City 29
Los Angeles 24
Lancaster 22
Bremen 21
Moscow 20
Munich 20
Changsha 19
Fairfield 19
Ottawa 19
University Park 17
Shenyang 16
Hong Kong 15
Princeton 15
Seattle 15
Boardman 14
Brussels 14
Hebei 13
Kunming 13
Beijing 12
Frankfurt am Main 12
Mountain View 12
The Dalles 12
Fremont 11
Guangzhou 11
Marseille 11
Norwalk 11
Düsseldorf 10
Jinan 10
Leawood 10
London 10
Shanghai 10
Chicago 9
Falls Church 9
Jiaxing 9
Lauterbourg 9
Rome 9
Verona 9
Augusta 8
Hangzhou 8
Portsmouth 8
Hanoi 7
Pune 7
San Francisco 7
Washington 7
Helsinki 6
Simi Valley 6
Toronto 6
Zhengzhou 6
Cambridge 5
Changchun 5
Tianjin 5
Andover 4
Busto Arsizio 4
Campinas 4
Carate Brianza 4
Hefei 4
Philadelphia 4
São Paulo 4
Tavagnacco 4
Amsterdam 3
Berlin 3
Brooklyn 3
Detroit 3
Edinburgh 3
Fuzhou 3
Guarulhos 3
Juazeiro do Norte 3
Juiz de Fora 3
Lanzhou 3
Manila 3
Miami 3
Modena 3
Montreal 3
Nuremberg 3
Paris 3
Porto Alegre 3
Prague 3
Totale 3.103
Salva come PNG Salva come JPEG
Nome #
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 235
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 189
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 167
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 162
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 149
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 148
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 147
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 145
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 145
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 135
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 134
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 132
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 132
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 123
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 118
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 117
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 117
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 116
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 114
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 111
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 110
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 108
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 108
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 107
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 106
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 103
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 102
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 102
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 101
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 99
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 98
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 96
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 94
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 92
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 90
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 89
Long term follow-up of Nevirapine-treated patients in a single centre cohort 88
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 88
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 88
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 86
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 86
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 85
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 83
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 82
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group 80
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study 80
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 80
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors 77
Interpretation systems for genotypic drug resistance of HIV-1 75
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 66
Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: a multicenter retrospective cohort study 63
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 62
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study 56
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 55
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort 49
Survival in HIV-infected patients after a cancer diagnosis in the cART era: Results of an Italian multicenter study 47
Combining epidemiological and genetic networks signifies the importance of early treatment in HIV-1 transmission 44
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 41
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 39
Totale 6.041
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.620
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202053 0 0 0 0 0 0 0 0 0 0 0 53
2020/2021471 12 52 14 48 53 31 49 8 82 16 91 15
2021/2022555 51 52 13 41 24 28 9 104 17 46 72 98
2022/20231.141 170 177 82 185 82 143 25 92 129 5 38 13
2023/2024570 19 151 9 59 23 169 17 4 6 9 69 35
2024/2025852 17 29 70 48 135 44 20 56 155 99 173 6
Totale 6.041